ClinicalTrials.gg
CompletedNCT03031938Updated Jun 25, 2021Results posted

Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

A Phase 3 interventional study of Investigational medical product (IMP) administered in parent study in Osteoarthritis, Cancer Pain and Recurrent Low Back Pain, sponsored by Pfizer. Completed at 6 sites in United States. Open to participants aged 0 Years to 2 Months. Per ClinicalTrials.gov, last updated 2021-06-25.

Sponsored by Pfizer · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
0 Years to 2 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Osteoarthritis by Pfizer — 2 open to participants now, 2 under way, 2 of them phase 3. Osteoarthritis · Pfizer.

Enrollment
34th of 37
4 · median 265
Started
2017
the only one that year
Phase 3
21 of 39
2 open now
Registered
37th of 39
by date

Among the 39 studies in Osteoarthritis by Pfizer, this one is the 34th largest by enrollment of the 37 interventional ones that give a count, is the only one that started in 2017, is one of 21 in phase 3, and was the 37th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

2 of the 39 studies in Osteoarthritis by Pfizer are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 0 Years to 2 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Osteoarthritis by Pfizer, or all of them as a file.
02

Study summary

A4091065 is a multicenter, prospective, cohort study with enhance physical an neurodevelopmental surveillance to characterize the outcomes related to the development of infants up to the age of 15 months who were potentially exposed to tanezumab, placebo or comparator via maternal exposure or in utero in any tanezumb study.

Read the detailed description

A4091065 is a long term observational follow up study of subjects from tanezumab interventional studies A4091056, A4091057, A4091058, A4091059, A4091061 or A4091063

03

Conditions studied

  • Osteoarthritis
  • Cancer Pain
  • Recurrent Low Back Pain

Keywords

  • Exposure in utero in tanezumab program
04

Who can participate

Ages eligible
0 Years to 2 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is an infant born to a mother who was exposed to study drug on a tanezumab clinical study.
  • The infant's mother (who was the tanezumab clinical study participant) must review, agree and sign an document explaining the details of the perinatal and post natal follow up. Where local regulations mandate, the male parent would also review and sign the informed consent.
  • Parents or legal guardian must be willing and able to comply with scheduled visits and study procedures.

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria for participating in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Other
    Cohort 1

    Long term observational study of subjects from tanezumab parent study

    Drug: Investigational medical product (IMP) administered in parent study

Interventions

06

What researchers measure

Primary outcomes

  1. Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

    Occipital-frontal head circumference of participants in centimeter (cm) was reported.

    Time frame: Any visit during participants' age from 0 to 2 Months

  2. Occipital-frontal Head Circumference at 8 Months of Participant's Age

    Occipital-frontal head circumference of participants in centimeter (cm) was reported.

    Time frame: At 8 Months of participants' age

  3. Occipital-frontal Head Circumference at 15 Months of Participant's Age

    Occipital-frontal head circumference of participants in centimeter (cm) was reported.

    Time frame: At 15 Months of participants' age

  4. Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 3 Months of Participant's Age

    Occipital-frontal head circumference of participants in centimeter (cm) was reported.

    Time frame: Any visit during participants' age from 0 to 3 Months

  5. Occipital-frontal Head Circumference During Greater Than (>) 3 to <=6 Months of Participant's Age

    Occipital-frontal head circumference of participants in cm was reported.

    Time frame: Any visit during participants' age above 3 Months and up to 6 Months

  6. Occipital-frontal Head Circumference During >6 to <=9 Months of Participant's Age

    Occipital-frontal head circumference of participants in cm was reported.

    Time frame: Any visit during participants' age above 6 Months and up to 9 Months

  7. Occipital-frontal Head Circumference During >15 to <=18 Months of Participant's Age

    Occipital-frontal head circumference of participants in cm was reported.

    Time frame: Any visit during participants' age above 15 Months and up to 18 Months

  8. Occipital-frontal Head Circumference During >21 to <=24 Months of Participant's Age

    Occipital-frontal head circumference of participants in cm was reported.

    Time frame: Any visit during participants' age above 21 Months and up to 24 Months

  9. Occipital-frontal Head Circumference During >24 to <=30 Months of Participant's Age

    Occipital-frontal head circumference of participants in cm was reported.

    Time frame: Any visit during participants' age above 24 Months and up to 30 Months

  10. Body Length During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

    Body length of participants in cm was reported.

    Time frame: Any visit during participants' age from 0 to 2 Months

  11. Body Length at 8 Months of Participant's Age

    Body length of participants in cm was reported.

    Time frame: At 8 Months of participant's age

  12. Body Length at 15 Months of Participant's Age

    Body length of participants in cm was reported.

    Time frame: At 15 Months of participant's age

  13. Body Length During 0 to <=3 Months of Participant's Age

    Body length of participants in cm was reported.

    Time frame: Any visit during participants' age from 0 to 3 Months

  14. Body Length During >3 to <=6 Months of Participant's Age

    Body length of participants in cm was reported.

    Time frame: Any visit during participants' age above 3 Months and up to 6 Months

  15. Body Length During >6 to <=9 Months of Participant's Age

    Body length of participants in cm was reported.

    Time frame: Any visit during participants' age above 6 Months and up to 9 Months

  16. Body Length During >15 to <=18 Months of Participant's Age

    Body length of participants in cm was reported.

    Time frame: Any visit during participants' age above 15 Months and up to 18 Months

  17. Body Length During >21 to <=24 Months of Participant's Age

    Body length of participants in cm was reported.

    Time frame: Any visit during participants' age above 21 Months and up to 24 Months

  18. Body Length During >24 to <=30 Months of Participant's Age

    Body length of participants in cm was reported.

    Time frame: Any visit during participants' age above 24 Months and up to 30 Months

  19. Body Weight During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

    Body weight of participants in kilogram (kg) was reported.

    Time frame: Any visit during participants' age from 0 to 2 Months

  20. Body Weight at 8 Months of Participant's Age

    Body weight of participants in kilogram (kg) was reported.

    Time frame: At 8 Months of participants' age

  21. Body Weight at 15 Months of Participant's Age

    Body weight of participants in kilogram (kg) was reported.

    Time frame: At 15 Months of participants' age

  22. Body Weight During 0 to <=3 Months of Participant's Age

    Body weight of participants in kilogram (kg) was reported.

    Time frame: Any visit during participants' age from 0 to 3 Months

  23. Body Weight During >3 to <=6 Months of Participant's Age

    Body weight of participants in kg was reported.

    Time frame: Any visit during participants' age above 3 Months and up to 6 Months

  24. Body Weight During >6 to <=9 Months of Participant's Age

    Body weight of participants in kg was reported.

    Time frame: Any visit during participants' age above 6 Months and up to 9 Months

  25. Body Weight During >15 to <=18 Months of Participant's Age

    Body weight of participants in kg was reported.

    Time frame: Any visit during participants' age above 15 Months and up to 18 Months

  26. Body Weight During >21 to <=24 Months of Participant's Age

    Body weight of participants in kg was reported.

    Time frame: Any visit during participants' age above 21 Months and up to 24 Months

  27. Body Weight During >24 to <=30 Months of Participant's Age

    Body weight of participants in kg was reported.

    Time frame: Any visit during participants' age above 24 Months up to 30 Months

  28. Systolic and Diastolic Blood Pressure During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

    Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

    Time frame: Any visit during participants' age from 0 to 2 Months

  29. Systolic and Diastolic Blood Pressure at 8 Months of Participant's Age

    Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

    Time frame: At 8 Months of participants' age

  30. Systolic and Diastolic Blood Pressure at 15 Months of Participant's Age

    Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

    Time frame: At 15 Months participants' age

  31. Systolic and Diastolic Blood Pressure During 0 to <=3 Months of Participant's Age

    Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

    Time frame: Any visit during participants' age from 0 to 3 Months

  32. Systolic and Diastolic Blood Pressure During >3 to <=6 Months of Participant's Age

    Systolic and diastolic blood pressure of participants in mmHg was reported.

    Time frame: Any visit during participants' age above 3 Months and up to 6 Months

  33. Systolic and Diastolic Blood Pressure During >6 to <=9 Months of Participant's Age

    Systolic and diastolic blood pressure of participants in mmHg was reported.

    Time frame: Any visit during participants' age above 6 Months and up to 9 Months

  34. Systolic and Diastolic Blood Pressure During >15 to <=18 Months of Participant's Age

    Systolic and diastolic blood pressure of participants in mmHg was reported.

    Time frame: Any visit during participants' age above 15 Months and up to 18 Months

  35. Systolic and Diastolic Blood Pressure During >21 to <=24 Months of Participant's Age

    Systolic and diastolic blood pressure of participants in mmHg was reported.

    Time frame: Any visit during participants' age above 21 Months and up to 24 Months

  36. Systolic and Diastolic Blood Pressure During >24 to <=30 Months of Participant's Age

    Systolic and diastolic blood pressure of participants in mmHg was reported.

    Time frame: Any visit during participants' age above 24 Months and up to 30 Months

  37. Pulse Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

    Pulse rate of participants in beats per minute was reported.

    Time frame: Any visit during participants' age from 0 to 2 Months

  38. Pulse Rate at 8 Months of Participant's Age

    Pulse rate of participants in beats per minute was reported.

    Time frame: At 8 Months of participants' age

  39. Pulse Rate at 15 Months of Participant's Age

    Pulse rate of participants in beats per minute was reported.

    Time frame: At 15 Months of participants' age

  40. Pulse Rate During 0 to <=3 Months of Participant's Age

    Pulse rate of participants in beats per minute was reported.

    Time frame: Any visit during participants' age from 0 to 3 Months

  41. Pulse Rate During >3 to <=6 Months of Participant's Age

    Pulse rate of participants in beats per minute was reported.

    Time frame: Any visit during participants' age above 3 Months and up to 6 Months

  42. Pulse Rate During >6 to <=9 Months of Participant's Age

    Pulse rate of participants in beats per minute was reported.

    Time frame: Any visit during participants' age above 6 Months and up to 9 Months

  43. Pulse Rate During >15 to <=18 Months of Participant's Age

    Pulse rate of participants in beats per minute was reported.

    Time frame: Any visit during participants' age above 15 Months and up to 18 Months

  44. Pulse Rate During >21 to <=24 Months of Participant's Age

    Pulse rate of participants in beats per minute was reported.

    Time frame: Any visit during participants' age above 21 Months and up to 24 Months

  45. Pulse Rate During >24 to <=30 Months of Participant's Age

    Pulse rate of participants in beats per minute was reported.

    Time frame: Any visit during participants' age above 24 Months and up to 30 Months

  46. Temperature During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

    Temperature of participants in degree Celsius was reported.

    Time frame: Any visit during participants' age from 0 to 2 Months

  47. Temperature at 8 Months of Participant's Age

    Temperature of participants in degree Celsius was reported.

    Time frame: At 8 Months of participants' age

  48. Temperature at 15 Months of Participant's Age

    Temperature of participants in degree Celsius was reported.

    Time frame: At 15 Months of participants' age

  49. Temperature During 0 to <=3 Months of Participant's Age

    Temperature of participants in degree Celsius was reported.

    Time frame: Any visit during participants' age from 0 to 3 Months

  50. Temperature During >3 to <=6 Months of Participant's Age

    Temperature of participants in degree Celsius was reported.

    Time frame: Any visit during participants' age above 3 Months and up to 6 Months

  51. Temperature During >6 to <=9 Months of Participant's Age

    Temperature of participants in degree Celsius was reported.

    Time frame: Any visit during participants' age above 6 Months and up to 9 Months

  52. Temperature During >15 to <=18 Months of Participant's Age

    Temperature of participants in degree Celsius was reported.

    Time frame: Any visit during participants' age above 15 Months and up to 18 Months

  53. Temperature During >21 to <=24 Months of Participant's Age

    Temperature of participants in degree Celsius was reported.

    Time frame: Any visit during participants' age above 21 Months and up to 24 Months

  54. Temperature During >24 to <=30 Months of Participant's Age

    Temperature of participants in degree Celsius was reported.

    Time frame: Any visit during participants' age above 24 Months and up to 30 Months

  55. Respiratory Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

    Respiratory rate of participants in breaths per minute was reported.

    Time frame: Any visit during participants' age from 0 to 2 Months

  56. Respiratory Rate at 8 Months of Participant's Age

    Respiratory rate of participants in breaths per minute was reported.

    Time frame: At 8 Months of participants' age

  57. Respiratory Rate at 15 Months of Participant's Age

    Respiratory rate of participants in breaths per minute was reported.

    Time frame: At 15 Months participants' age

  58. Respiratory Rate During 0 to <=3 Months of Participant's Age

    Respiratory rate of participants in breaths per minute was reported.

    Time frame: Any visit during participants' age from 0 to 3 Months

  59. Respiratory Rate During >3 to <=6 Months of Participant's Age

    Respiratory rate of participants in breaths per minute was reported.

    Time frame: Any visit during participants' age above 3 Months and up to 6 Months

  60. Respiratory Rate During >6 to <=9 Months of Participant's Age

    Respiratory rate of participants in breaths per minute was reported.

    Time frame: Any visit during participants' age above 6 Months and up to 9 Months

  61. Respiratory Rate During >15 to <=18 Months of Participant's Age

    Respiratory rate of participants in breaths per minute was reported.

    Time frame: Any visit during participants' age above 15 Months and up to 18 Months

  62. Respiratory Rate During >21 to <=24 Months of Participant's Age

    Respiratory rate of participants in breaths per minute was reported.

    Time frame: Any visit during participants' age above 21 Months and up to 24 Months

  63. Respiratory Rate During >24 to <=30 Months of Participant's Age

    Respiratory rate of participants in breaths per minute was reported.

    Time frame: Any visit during participants' age above 24 Months and up to 30 Months

  64. Number of Participants With Abnormal Neurological Examination Findings During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

    Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

    Time frame: Any visit during participants' age from 0 to 2 Months

  65. Number of Participants With Abnormal Neurological Examination Findings at 8 Months of Participant's Age

    Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

    Time frame: At 8 Months of participants' age

  66. Number of Participants With Abnormal Neurological Examination Findings at 15 Months of Participant's Age

    Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

    Time frame: At 15 Months of participants' age

  67. Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 1 (Month 20 of Participant's Age)

    Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

    Time frame: Follow-up Visit 1 (At the age of Month 20)

  68. Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 2 (Month 26 of Participant's Age)

    Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

    Time frame: Follow-up Visit 2 (At the age of 26 Months)

  69. Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 8 of Participant's Age

    BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.

    Time frame: At 8 Months of participants' age

  70. Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 15 of Participant's Age

    BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.

    Time frame: At 15 Months of participants' age

  71. Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 1 (Month 20 of Participant's Age)

    BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.

    Time frame: Follow-up Visit 1 (At the age of Month 20)

  72. Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 2 (Month 26 of Participant's Age)

    BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance. Data collected at age of 26 months used 24 months' age items.

    Time frame: Follow-up Visit 2 (At the age of Month 26)

  73. Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 8 of Participant's Age

    REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

    Time frame: At 8 Months of participants' age

  74. Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 15 of Participant's Age

    REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

    Time frame: At 15 Months of participants' age

  75. Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 1 (Month 20 of Participant's Age)

    REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

    Time frame: Follow-up Visit 1 (At the age of Month 20)

  76. Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 2 (Month 26 of Participant's Age)

    REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

    Time frame: Follow-up Visit 2 (At the age of Month 26)

07

Results

Posted Jun 25, 2021

Participant flow

Infants to be enrolled were exposed potentially to tanezumab, placebo or comparator via maternal exposure at conception or in-utero during tanezumab clinical program, in any of the following studies: A4091056 (NCT02697773), A4091057 (NCT02709486), A4091058 (NCT02528188), A4091059 (NCT02528253), A4091061 (NCT02609828) or A4091063 (NCT02725411). Total 4 eligible infants were enrolled. Out of 4, 2 had tanezumab exposure, 2 had comparator (tramadol) exposure and none had placebo exposure.

Participant flow — Overall Study
MilestoneMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Started22
Completed12
Not completed10
Withdrew: Death10

Outcome measures

PrimaryOccipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

Occipital-frontal head circumference of participants in centimeter (cm) was reported.

Time frame:
Any visit during participants' age from 0 to 2 Months
Reported as:
Mean · cm
Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age38.738.7 ± 1.63
PrimaryOccipital-frontal Head Circumference at 8 Months of Participant's Age

Occipital-frontal head circumference of participants in centimeter (cm) was reported.

Time frame:
At 8 Months of participants' age
Reported as:
Mean · cm
Occipital-frontal Head Circumference at 8 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Occipital-frontal Head Circumference at 8 Months of Participant's Age47.0 ± 1.4147.2 ± 1.44
PrimaryOccipital-frontal Head Circumference at 15 Months of Participant's Age

Occipital-frontal head circumference of participants in centimeter (cm) was reported.

Time frame:
At 15 Months of participants' age
Reported as:
Mean · cm
Occipital-frontal Head Circumference at 15 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Occipital-frontal Head Circumference at 15 Months of Participant's Age49.2 ± 2.3348.9 ± 2.69
PrimaryOccipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 3 Months of Participant's Age

Occipital-frontal head circumference of participants in centimeter (cm) was reported.

Time frame:
Any visit during participants' age from 0 to 3 Months
Reported as:
Mean · cm
Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 3 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 3 Months of Participant's Age38.738.7 ± 1.63
PrimaryOccipital-frontal Head Circumference During Greater Than (>) 3 to <=6 Months of Participant's Age

Occipital-frontal head circumference of participants in cm was reported.

Time frame:
Any visit during participants' age above 3 Months and up to 6 Months
Reported as:
Mean · cm
Occipital-frontal Head Circumference During Greater Than (>) 3 to <=6 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Occipital-frontal Head Circumference During Greater Than (>) 3 to <=6 Months of Participant's Age44.0—
PrimaryOccipital-frontal Head Circumference During >6 to <=9 Months of Participant's Age

Occipital-frontal head circumference of participants in cm was reported.

Time frame:
Any visit during participants' age above 6 Months and up to 9 Months
Reported as:
Mean · cm
Occipital-frontal Head Circumference During >6 to <=9 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Occipital-frontal Head Circumference During >6 to <=9 Months of Participant's Age47.0 ± 1.4147.2 ± 1.44
PrimaryOccipital-frontal Head Circumference During >15 to <=18 Months of Participant's Age

Occipital-frontal head circumference of participants in cm was reported.

Time frame:
Any visit during participants' age above 15 Months and up to 18 Months
Reported as:
Mean · cm
Occipital-frontal Head Circumference During >15 to <=18 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Occipital-frontal Head Circumference During >15 to <=18 Months of Participant's Age49.2 ± 2.3348.9 ± 2.69
PrimaryOccipital-frontal Head Circumference During >21 to <=24 Months of Participant's Age

Occipital-frontal head circumference of participants in cm was reported.

Time frame:
Any visit during participants' age above 21 Months and up to 24 Months
Reported as:
Mean · cm
Occipital-frontal Head Circumference During >21 to <=24 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Occipital-frontal Head Circumference During >21 to <=24 Months of Participant's Age49.0—
PrimaryOccipital-frontal Head Circumference During >24 to <=30 Months of Participant's Age

Occipital-frontal head circumference of participants in cm was reported.

Time frame:
Any visit during participants' age above 24 Months and up to 30 Months
Reported as:
Mean · cm
Occipital-frontal Head Circumference During >24 to <=30 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Occipital-frontal Head Circumference During >24 to <=30 Months of Participant's Age50.5—
PrimaryBody Length During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

Body length of participants in cm was reported.

Time frame:
Any visit during participants' age from 0 to 2 Months
Reported as:
Mean · cm
Body Length During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Length During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age54.656.5 ± 1.41
PrimaryBody Length at 8 Months of Participant's Age

Body length of participants in cm was reported.

Time frame:
At 8 Months of participant's age
Reported as:
Mean · cm
Body Length at 8 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Length at 8 Months of Participant's Age73.6 ± 3.4573.7 ± 1.80
PrimaryBody Length at 15 Months of Participant's Age

Body length of participants in cm was reported.

Time frame:
At 15 Months of participant's age
Reported as:
Mean · cm
Body Length at 15 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Length at 15 Months of Participant's Age82.3 ± 3.9581.3 ± 0.00
PrimaryBody Length During 0 to <=3 Months of Participant's Age

Body length of participants in cm was reported.

Time frame:
Any visit during participants' age from 0 to 3 Months
Reported as:
Mean · cm
Body Length During 0 to <=3 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Length During 0 to <=3 Months of Participant's Age54.656.5 ± 1.41
PrimaryBody Length During >3 to <=6 Months of Participant's Age

Body length of participants in cm was reported.

Time frame:
Any visit during participants' age above 3 Months and up to 6 Months
Reported as:
Mean · cm
Body Length During >3 to <=6 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Length During >3 to <=6 Months of Participant's Age72.4—
PrimaryBody Length During >6 to <=9 Months of Participant's Age

Body length of participants in cm was reported.

Time frame:
Any visit during participants' age above 6 Months and up to 9 Months
Reported as:
Mean · cm
Body Length During >6 to <=9 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Length During >6 to <=9 Months of Participant's Age73.6 ± 3.4573.7 ± 1.80
PrimaryBody Length During >15 to <=18 Months of Participant's Age

Body length of participants in cm was reported.

Time frame:
Any visit during participants' age above 15 Months and up to 18 Months
Reported as:
Mean · cm
Body Length During >15 to <=18 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Length During >15 to <=18 Months of Participant's Age82.3 ± 3.9581.3 ± 0.00
PrimaryBody Length During >21 to <=24 Months of Participant's Age

Body length of participants in cm was reported.

Time frame:
Any visit during participants' age above 21 Months and up to 24 Months
Reported as:
Mean · cm
Body Length During >21 to <=24 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Length During >21 to <=24 Months of Participant's Age92.5—
PrimaryBody Length During >24 to <=30 Months of Participant's Age

Body length of participants in cm was reported.

Time frame:
Any visit during participants' age above 24 Months and up to 30 Months
Reported as:
Mean · cm
Body Length During >24 to <=30 Months of Participant's Age
cmMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Length During >24 to <=30 Months of Participant's Age97.8—
PrimaryBody Weight During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

Body weight of participants in kilogram (kg) was reported.

Time frame:
Any visit during participants' age from 0 to 2 Months
Reported as:
Mean · kg
Body Weight During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
kgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Weight During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age3.45.8 ± 1.03
PrimaryBody Weight at 8 Months of Participant's Age

Body weight of participants in kilogram (kg) was reported.

Time frame:
At 8 Months of participants' age
Reported as:
Mean · kg
Body Weight at 8 Months of Participant's Age
kgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Weight at 8 Months of Participant's Age11.3 ± 2.5011.6 ± 0.39
PrimaryBody Weight at 15 Months of Participant's Age

Body weight of participants in kilogram (kg) was reported.

Time frame:
At 15 Months of participants' age
Reported as:
Mean · kg
Body Weight at 15 Months of Participant's Age
kgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Weight at 15 Months of Participant's Age13.6 ± 2.5313.1 ± 1.09
PrimaryBody Weight During 0 to <=3 Months of Participant's Age

Body weight of participants in kilogram (kg) was reported.

Time frame:
Any visit during participants' age from 0 to 3 Months
Reported as:
Mean · kg
Body Weight During 0 to <=3 Months of Participant's Age
kgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Weight During 0 to <=3 Months of Participant's Age3.45.8 ± 1.03
PrimaryBody Weight During >3 to <=6 Months of Participant's Age

Body weight of participants in kg was reported.

Time frame:
Any visit during participants' age above 3 Months and up to 6 Months
Reported as:
Mean · kg
Body Weight During >3 to <=6 Months of Participant's Age
kgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Weight During >3 to <=6 Months of Participant's Age11.3—
PrimaryBody Weight During >6 to <=9 Months of Participant's Age

Body weight of participants in kg was reported.

Time frame:
Any visit during participants' age above 6 Months and up to 9 Months
Reported as:
Mean · kg
Body Weight During >6 to <=9 Months of Participant's Age
kgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Weight During >6 to <=9 Months of Participant's Age11.3 ± 2.5011.6 ± 0.39
PrimaryBody Weight During >15 to <=18 Months of Participant's Age

Body weight of participants in kg was reported.

Time frame:
Any visit during participants' age above 15 Months and up to 18 Months
Reported as:
Mean · kg
Body Weight During >15 to <=18 Months of Participant's Age
kgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Weight During >15 to <=18 Months of Participant's Age13.6 ± 2.5313.1 ± 1.09
PrimaryBody Weight During >21 to <=24 Months of Participant's Age

Body weight of participants in kg was reported.

Time frame:
Any visit during participants' age above 21 Months and up to 24 Months
Reported as:
Mean · kg
Body Weight During >21 to <=24 Months of Participant's Age
kgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Weight During >21 to <=24 Months of Participant's Age16.0—
PrimaryBody Weight During >24 to <=30 Months of Participant's Age

Body weight of participants in kg was reported.

Time frame:
Any visit during participants' age above 24 Months up to 30 Months
Reported as:
Mean · kg
Body Weight During >24 to <=30 Months of Participant's Age
kgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Body Weight During >24 to <=30 Months of Participant's Age18.4—
PrimarySystolic and Diastolic Blood Pressure During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

Time frame:
Any visit during participants' age from 0 to 2 Months
Reported as:
Mean · mmHg
Systolic and Diastolic Blood Pressure During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
mmHgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Systolic Blood Pressure90.0NA ± NA
Diastolic Blood Pressure60.0NA ± NA
PrimarySystolic and Diastolic Blood Pressure at 8 Months of Participant's Age

Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

Time frame:
At 8 Months of participants' age
Reported as:
Mean · mmHg
Systolic and Diastolic Blood Pressure at 8 Months of Participant's Age
mmHgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Systolic Blood Pressure95.5 ± 19.0982.0
Diastolic Blood Pressure66.0 ± 8.4940.0
PrimarySystolic and Diastolic Blood Pressure at 15 Months of Participant's Age

Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

Time frame:
At 15 Months participants' age
Reported as:
Mean · mmHg
Systolic and Diastolic Blood Pressure at 15 Months of Participant's Age
mmHgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Systolic Blood Pressure94.5 ± 7.7880.0 ± 2.83
Diastolic Blood Pressure58.5 ± 2.1243.0 ± 4.24
PrimarySystolic and Diastolic Blood Pressure During 0 to <=3 Months of Participant's Age

Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

Time frame:
Any visit during participants' age from 0 to 3 Months
Reported as:
Mean · mmHg
Systolic and Diastolic Blood Pressure During 0 to <=3 Months of Participant's Age
mmHgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Systolic Blood Pressure90.0NA ± NA
Diastolic Blood Pressure60.0NA ± NA
PrimarySystolic and Diastolic Blood Pressure During >3 to <=6 Months of Participant's Age

Systolic and diastolic blood pressure of participants in mmHg was reported.

Time frame:
Any visit during participants' age above 3 Months and up to 6 Months

No measurements were reported for this outcome.

PrimarySystolic and Diastolic Blood Pressure During >6 to <=9 Months of Participant's Age

Systolic and diastolic blood pressure of participants in mmHg was reported.

Time frame:
Any visit during participants' age above 6 Months and up to 9 Months
Reported as:
Mean · mmHg
Systolic and Diastolic Blood Pressure During >6 to <=9 Months of Participant's Age
mmHgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Systolic Blood Pressure95.5 ± 19.0982.0
Diastolic Blood Pressure66.0 ± 8.4940.0
PrimarySystolic and Diastolic Blood Pressure During >15 to <=18 Months of Participant's Age

Systolic and diastolic blood pressure of participants in mmHg was reported.

Time frame:
Any visit during participants' age above 15 Months and up to 18 Months
Reported as:
Mean · mmHg
Systolic and Diastolic Blood Pressure During >15 to <=18 Months of Participant's Age
mmHgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Systolic Blood Pressure94.5 ± 7.7880.0 ± 2.83
Diastolic Blood Pressure58.5 ± 2.1243.0 ± 4.24
PrimarySystolic and Diastolic Blood Pressure During >21 to <=24 Months of Participant's Age

Systolic and diastolic blood pressure of participants in mmHg was reported.

Time frame:
Any visit during participants' age above 21 Months and up to 24 Months
Reported as:
Mean · mmHg
Systolic and Diastolic Blood Pressure During >21 to <=24 Months of Participant's Age
mmHgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Systolic Blood Pressure123.0—
Diastolic Blood Pressure78.0—
PrimarySystolic and Diastolic Blood Pressure During >24 to <=30 Months of Participant's Age

Systolic and diastolic blood pressure of participants in mmHg was reported.

Time frame:
Any visit during participants' age above 24 Months and up to 30 Months
Reported as:
Mean · mmHg
Systolic and Diastolic Blood Pressure During >24 to <=30 Months of Participant's Age
mmHgMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Systolic Blood Pressure101.0—
Diastolic Blood Pressure55.0—
PrimaryPulse Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

Pulse rate of participants in beats per minute was reported.

Time frame:
Any visit during participants' age from 0 to 2 Months
Reported as:
Mean · beats per minute
Pulse Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
beats per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Pulse Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age124.0144.0 ± 15.56
PrimaryPulse Rate at 8 Months of Participant's Age

Pulse rate of participants in beats per minute was reported.

Time frame:
At 8 Months of participants' age
Reported as:
Mean · beats per minute
Pulse Rate at 8 Months of Participant's Age
beats per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Pulse Rate at 8 Months of Participant's Age117.0 ± 15.56121.0 ± 4.24
PrimaryPulse Rate at 15 Months of Participant's Age

Pulse rate of participants in beats per minute was reported.

Time frame:
At 15 Months of participants' age
Reported as:
Mean · beats per minute
Pulse Rate at 15 Months of Participant's Age
beats per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Pulse Rate at 15 Months of Participant's Age108.5 ± 20.51116.0 ± 5.66
PrimaryPulse Rate During 0 to <=3 Months of Participant's Age

Pulse rate of participants in beats per minute was reported.

Time frame:
Any visit during participants' age from 0 to 3 Months
Reported as:
Mean · beats per minute
Pulse Rate During 0 to <=3 Months of Participant's Age
beats per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Pulse Rate During 0 to <=3 Months of Participant's Age124.0144.0 ± 15.56
PrimaryPulse Rate During >3 to <=6 Months of Participant's Age

Pulse rate of participants in beats per minute was reported.

Time frame:
Any visit during participants' age above 3 Months and up to 6 Months
Reported as:
Mean · beats per minute
Pulse Rate During >3 to <=6 Months of Participant's Age
beats per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Pulse Rate During >3 to <=6 Months of Participant's Age128.0—
PrimaryPulse Rate During >6 to <=9 Months of Participant's Age

Pulse rate of participants in beats per minute was reported.

Time frame:
Any visit during participants' age above 6 Months and up to 9 Months
Reported as:
Mean · beats per minute
Pulse Rate During >6 to <=9 Months of Participant's Age
beats per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Pulse Rate During >6 to <=9 Months of Participant's Age117.0 ± 15.56121.0 ± 4.24
PrimaryPulse Rate During >15 to <=18 Months of Participant's Age

Pulse rate of participants in beats per minute was reported.

Time frame:
Any visit during participants' age above 15 Months and up to 18 Months
Reported as:
Mean · beats per minute
Pulse Rate During >15 to <=18 Months of Participant's Age
beats per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Pulse Rate During >15 to <=18 Months of Participant's Age108.5 ± 20.51116.0 ± 5.66
PrimaryPulse Rate During >21 to <=24 Months of Participant's Age

Pulse rate of participants in beats per minute was reported.

Time frame:
Any visit during participants' age above 21 Months and up to 24 Months
Reported as:
Mean · beats per minute
Pulse Rate During >21 to <=24 Months of Participant's Age
beats per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Pulse Rate During >21 to <=24 Months of Participant's Age118.0—
PrimaryPulse Rate During >24 to <=30 Months of Participant's Age

Pulse rate of participants in beats per minute was reported.

Time frame:
Any visit during participants' age above 24 Months and up to 30 Months
Reported as:
Mean · beats per minute
Pulse Rate During >24 to <=30 Months of Participant's Age
beats per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Pulse Rate During >24 to <=30 Months of Participant's Age118.0—
PrimaryTemperature During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

Temperature of participants in degree Celsius was reported.

Time frame:
Any visit during participants' age from 0 to 2 Months
Reported as:
Mean · degree Celsius
Temperature During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
degree CelsiusMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Temperature During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age36.236.6 ± 0.08
PrimaryTemperature at 8 Months of Participant's Age

Temperature of participants in degree Celsius was reported.

Time frame:
At 8 Months of participants' age
Reported as:
Mean · degree Celsius
Temperature at 8 Months of Participant's Age
degree CelsiusMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Temperature at 8 Months of Participant's Age36.3 ± 0.2736.7 ± 0.08
PrimaryTemperature at 15 Months of Participant's Age

Temperature of participants in degree Celsius was reported.

Time frame:
At 15 Months of participants' age
Reported as:
Mean · degree Celsius
Temperature at 15 Months of Participant's Age
degree CelsiusMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Temperature at 15 Months of Participant's Age36.1 ± 0.4736.5 ± 0.04
PrimaryTemperature During 0 to <=3 Months of Participant's Age

Temperature of participants in degree Celsius was reported.

Time frame:
Any visit during participants' age from 0 to 3 Months
Reported as:
Mean · degree Celsius
Temperature During 0 to <=3 Months of Participant's Age
degree CelsiusMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Temperature During 0 to <=3 Months of Participant's Age36.236.6 ± 0.08
PrimaryTemperature During >3 to <=6 Months of Participant's Age

Temperature of participants in degree Celsius was reported.

Time frame:
Any visit during participants' age above 3 Months and up to 6 Months
Reported as:
Mean · degree Celsius
Temperature During >3 to <=6 Months of Participant's Age
degree CelsiusMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Temperature During >3 to <=6 Months of Participant's Age36.4—
PrimaryTemperature During >6 to <=9 Months of Participant's Age

Temperature of participants in degree Celsius was reported.

Time frame:
Any visit during participants' age above 6 Months and up to 9 Months
Reported as:
Mean · degree Celsius
Temperature During >6 to <=9 Months of Participant's Age
degree CelsiusMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Temperature During >6 to <=9 Months of Participant's Age36.3 ± 0.2736.7 ± 0.08
PrimaryTemperature During >15 to <=18 Months of Participant's Age

Temperature of participants in degree Celsius was reported.

Time frame:
Any visit during participants' age above 15 Months and up to 18 Months
Reported as:
Mean · degree Celsius
Temperature During >15 to <=18 Months of Participant's Age
degree CelsiusMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Temperature During >15 to <=18 Months of Participant's Age36.1 ± 0.4736.5 ± 0.04
PrimaryTemperature During >21 to <=24 Months of Participant's Age

Temperature of participants in degree Celsius was reported.

Time frame:
Any visit during participants' age above 21 Months and up to 24 Months
Reported as:
Mean · degree Celsius
Temperature During >21 to <=24 Months of Participant's Age
degree CelsiusMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Temperature During >21 to <=24 Months of Participant's Age36.4—
PrimaryTemperature During >24 to <=30 Months of Participant's Age

Temperature of participants in degree Celsius was reported.

Time frame:
Any visit during participants' age above 24 Months and up to 30 Months
Reported as:
Mean · degree Celsius
Temperature During >24 to <=30 Months of Participant's Age
degree CelsiusMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Temperature During >24 to <=30 Months of Participant's Age36.3—
PrimaryRespiratory Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

Respiratory rate of participants in breaths per minute was reported.

Time frame:
Any visit during participants' age from 0 to 2 Months
Reported as:
Mean · breaths per minute
Respiratory Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
breaths per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Respiratory Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age30.057.0 ± 9.90
PrimaryRespiratory Rate at 8 Months of Participant's Age

Respiratory rate of participants in breaths per minute was reported.

Time frame:
At 8 Months of participants' age
Reported as:
Mean · breaths per minute
Respiratory Rate at 8 Months of Participant's Age
breaths per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Respiratory Rate at 8 Months of Participant's Age33.0 ± 1.4134.0 ± 2.83
PrimaryRespiratory Rate at 15 Months of Participant's Age

Respiratory rate of participants in breaths per minute was reported.

Time frame:
At 15 Months participants' age
Reported as:
Mean · breaths per minute
Respiratory Rate at 15 Months of Participant's Age
breaths per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Respiratory Rate at 15 Months of Participant's Age34.0 ± 14.1427.0 ± 1.41
PrimaryRespiratory Rate During 0 to <=3 Months of Participant's Age

Respiratory rate of participants in breaths per minute was reported.

Time frame:
Any visit during participants' age from 0 to 3 Months
Reported as:
Mean · breaths per minute
Respiratory Rate During 0 to <=3 Months of Participant's Age
breaths per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Respiratory Rate During 0 to <=3 Months of Participant's Age30.057.0 ± 9.90
PrimaryRespiratory Rate During >3 to <=6 Months of Participant's Age

Respiratory rate of participants in breaths per minute was reported.

Time frame:
Any visit during participants' age above 3 Months and up to 6 Months
Reported as:
Mean · breaths per minute
Respiratory Rate During >3 to <=6 Months of Participant's Age
breaths per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Respiratory Rate During >3 to <=6 Months of Participant's Age44.0—
PrimaryRespiratory Rate During >6 to <=9 Months of Participant's Age

Respiratory rate of participants in breaths per minute was reported.

Time frame:
Any visit during participants' age above 6 Months and up to 9 Months
Reported as:
Mean · breaths per minute
Respiratory Rate During >6 to <=9 Months of Participant's Age
breaths per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Respiratory Rate During >6 to <=9 Months of Participant's Age33.0 ± 1.4134.0 ± 2.83
PrimaryRespiratory Rate During >15 to <=18 Months of Participant's Age

Respiratory rate of participants in breaths per minute was reported.

Time frame:
Any visit during participants' age above 15 Months and up to 18 Months
Reported as:
Mean · breaths per minute
Respiratory Rate During >15 to <=18 Months of Participant's Age
breaths per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Respiratory Rate During >15 to <=18 Months of Participant's Age34.0 ± 14.1427.0 ± 1.41
PrimaryRespiratory Rate During >21 to <=24 Months of Participant's Age

Respiratory rate of participants in breaths per minute was reported.

Time frame:
Any visit during participants' age above 21 Months and up to 24 Months
Reported as:
Mean · breaths per minute
Respiratory Rate During >21 to <=24 Months of Participant's Age
breaths per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Respiratory Rate During >21 to <=24 Months of Participant's Age44.0—
PrimaryRespiratory Rate During >24 to <=30 Months of Participant's Age

Respiratory rate of participants in breaths per minute was reported.

Time frame:
Any visit during participants' age above 24 Months and up to 30 Months
Reported as:
Mean · breaths per minute
Respiratory Rate During >24 to <=30 Months of Participant's Age
breaths per minuteMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Respiratory Rate During >24 to <=30 Months of Participant's Age44.0—
PrimaryNumber of Participants With Abnormal Neurological Examination Findings During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age

Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

Time frame:
Any visit during participants' age from 0 to 2 Months
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Neurological Examination Findings During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
ParticipantsMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Number of Participants With Abnormal Neurological Examination Findings During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age00
PrimaryNumber of Participants With Abnormal Neurological Examination Findings at 8 Months of Participant's Age

Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

Time frame:
At 8 Months of participants' age
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Neurological Examination Findings at 8 Months of Participant's Age
ParticipantsMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Number of Participants With Abnormal Neurological Examination Findings at 8 Months of Participant's Age00
PrimaryNumber of Participants With Abnormal Neurological Examination Findings at 15 Months of Participant's Age

Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

Time frame:
At 15 Months of participants' age
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Neurological Examination Findings at 15 Months of Participant's Age
ParticipantsMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Number of Participants With Abnormal Neurological Examination Findings at 15 Months of Participant's Age10
PrimaryNumber of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 1 (Month 20 of Participant's Age)

Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

Time frame:
Follow-up Visit 1 (At the age of Month 20)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 1 (Month 20 of Participant's Age)
ParticipantsMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 1 (Month 20 of Participant's Age)10
PrimaryNumber of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 2 (Month 26 of Participant's Age)

Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

Time frame:
Follow-up Visit 2 (At the age of 26 Months)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 2 (Month 26 of Participant's Age)
ParticipantsMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 2 (Month 26 of Participant's Age)10
PrimaryBayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 8 of Participant's Age

BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.

Time frame:
At 8 Months of participants' age
Reported as:
Mean · units on a scale
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 8 of Participant's Age
units on a scaleMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 8 of Participant's AgeNA ± NANA ± NA
PrimaryBayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 15 of Participant's Age

BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.

Time frame:
At 15 Months of participants' age
Reported as:
Mean · units on a scale
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 15 of Participant's Age
units on a scaleMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 15 of Participant's AgeNA ± NANA ± NA
PrimaryBayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 1 (Month 20 of Participant's Age)

BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.

Time frame:
Follow-up Visit 1 (At the age of Month 20)
Reported as:
Mean · units on a scale
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 1 (Month 20 of Participant's Age)
units on a scaleMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 1 (Month 20 of Participant's Age)7—
PrimaryBayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 2 (Month 26 of Participant's Age)

BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance. Data collected at age of 26 months used 24 months' age items.

Time frame:
Follow-up Visit 2 (At the age of Month 26)
Reported as:
Mean · units on a scale
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 2 (Month 26 of Participant's Age)
units on a scaleMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 2 (Month 26 of Participant's Age)6—
PrimaryBzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 8 of Participant's Age

REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

Time frame:
At 8 Months of participants' age
Reported as:
Mean · units on a scale
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 8 of Participant's Age
units on a scaleMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 8 of Participant's AgeNA ± NANA ± NA
PrimaryBzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 15 of Participant's Age

REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

Time frame:
At 15 Months of participants' age
Reported as:
Mean · units on a scale
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 15 of Participant's Age
units on a scaleMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 15 of Participant's AgeNA ± NANA ± NA
PrimaryBzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 1 (Month 20 of Participant's Age)

REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

Time frame:
Follow-up Visit 1 (At the age of Month 20)
Reported as:
Mean · units on a scale
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 1 (Month 20 of Participant's Age)
units on a scaleMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 1 (Month 20 of Participant's Age)88—
PrimaryBzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 2 (Month 26 of Participant's Age)

REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

Time frame:
Follow-up Visit 2 (At the age of Month 26)
Reported as:
Mean · units on a scale
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 2 (Month 26 of Participant's Age)
units on a scaleMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 2 (Month 26 of Participant's Age)92—

Adverse events

Collected over From the participants' age of 0 month to maximum of 36 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maternal Exposure to Tanezumab1/2 (50%)1/2 (50%)1/2 (50%)
Maternal Exposure to Tramadol0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent serious events
Most frequent serious events
EventMaternal Exposure to TanezumabMaternal Exposure to Tramadol
DrowningGeneral disorders1/20/2
Most frequent other events
Most frequent other events
EventMaternal Exposure to TanezumabMaternal Exposure to Tramadol
Speech disorder/ Language development delayNervous system disorders1/20/2
Speech disorder developmental / Speech developmental delayNervous system disorders1/20/2

Baseline characteristics

Safety population included all participants who were enrolled into the study.

Age, Customized
Age, Customized(Participants)Maternal Exposure to TanezumabMaternal Exposure to TramadolTotal
Pre-term newborn - gestational age < 37 week000
Newborns (0-27 days)000
Infants and toddlers (28 days-23 months)224
Sex: Female, Male
Sex: Female, Male(Participants)Maternal Exposure to TanezumabMaternal Exposure to TramadolTotal
Female011
Male213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Maternal Exposure to TanezumabMaternal Exposure to TramadolTotal
Hispanic or Latino000
Not Hispanic or Latino224
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Maternal Exposure to TanezumabMaternal Exposure to TramadolTotal
Race — White022
Race — Black or African American101
Race — Other101
08

Study locations

6 sites
  • USC Keck School of Medicine
    Los Angeles, California 90033, United States
  • Gulfcoast Research Institute
    Sarasota, Florida 34232, United States
  • Kennedy and White Orthopaedic Center
    Sarasota, Florida 34232, United States
  • Pediatric Epilepsy & Neurology Specialists
    Tampa, Florida 33609, United States
  • Lafayette Clinical Research Group
    Lafayette, Indiana 47905, United States
  • Preferred Pediatrics
    Lafayette, Indiana 47905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jun 2020, 31 months.

Results were first posted in Jun 2021, 1 year after primary completion.

Of 60 industry-sponsored phase 3 interventional studies under Osteoarthritis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 31 months is above that.

Counting every sponsor, half of 84 studies reached it within 17 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2017
First posted
Jan 26, 2017
StartActual
Nov 3, 2017
Primary completionActual
Jun 4, 2020
CompletionActual
Jun 4, 2020
Results first posted
Jun 25, 2021
Last update
Jun 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03031938
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 26, 2017
Start date
Nov 3, 2017
Primary completion
Jun 4, 2020
Completion
Jun 4, 2020
Results posted
Jun 25, 2021
Last update
Jun 25, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inosine Monophosphate

Start the discussion